Tech Company Financing Transactions
Tavo Biotherapeutics Funding Round
Tavo Biotherapeutics secured a $17 million Series A investment round on 6/2/2026. Investors included Pureos Bioventures, Polaris Partners and Tau Capital.
Transaction Overview
Company Name
Announced On
6/2/2026
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support ongoing clinical and preclinical development activities for its TAV-001 and TAV-002 programs, expand its research capabilities, and progress toward upcoming clinical milestones.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
384 Forest Avenue 19
Laguna Beach, CA 92651
USA
Laguna Beach, CA 92651
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Tavo Biotherapeutics is a biotech company developing novel treatments for glaucoma and retinal diseases. By leveraging differentiated science and a deeply experienced team, we aim to develop transformative therapies that preserve vision by targeting the root biological mechanisms of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Berman
Chief Financial Officer
Graham Cooper
Chief Medical Officer
Federico Grossi
VP - Bus. Development
Joel Thompson
VP - R & D
Lukas Scheibler
Browse more venture capital transactions:
Prev: 6/2/2026: Findigs venture capital transaction
Next: 6/2/2026: Tilt venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs